{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:04:14Z","timestamp":1789038254278,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["WO2022063853"],"award-info":[{"award-number":["WO2022063853"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["WO2022064191"],"award-info":[{"award-number":["WO2022064191"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001273","name":"Children with Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["666908"],"award-info":[{"award-number":["666908"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018727","name":"UCL Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006581","name":"Centro de Investigaciones en Optica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ymthe.2024.03.032","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:03:49Z","timestamp":1711544629000},"page":"1672-1686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-1056","authenticated-orcid":false,"given":"Jenny","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Vetharoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Leon","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Havenith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolke","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"van Berkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sebire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumide K.","family":"Ogunbiyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-3911","authenticated-orcid":false,"given":"Persis J.","family":"Amrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.03.032_bib1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.hoc.2017.06.006","article-title":"Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy","volume":"31","author":"Kohn","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ymthe.2024.03.032_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.032_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel Gene Therapy for Non-beta(0)\/beta(0) Genotype beta-Thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.032_bib4","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.032_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.03.032_bib6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2024.03.032_bib7","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","first-page":"99","article-title":"Conditioning","author":"Nagler","year":"2019"},{"key":"10.1016\/j.ymthe.2024.03.032_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.03.032_bib9","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2021-153074","article-title":"JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Na\u00efve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)","volume":"138","author":"Agarwal","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.03.032_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2021-145524","article-title":"CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model","volume":"138","author":"Uchida","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/blood-2022-162406","volume":"140","author":"Westervelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib14","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood.V99.10.3566","article-title":"In vivo depletion of hematopoietic stem cells in the rat by an anti-CD45 (RT7) antibody","volume":"99","author":"Dahlke","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib15","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2002-08-2379","article-title":"Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation","volume":"101","author":"Wulf","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.03.032_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.03.032_bib18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2024.03.032_bib19","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.032_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41409-020-01000-3","article-title":"(90)Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma","volume":"56","author":"Tuazon","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2024.03.032_bib21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2024.03.032_bib22","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.tetlet.2017.10.010","article-title":"An optimised synthesis of SG3376, a non-cleavable antibody-drug conjugate pyrrolobenzodiazepine drug-linker","volume":"58","author":"Tiberghien","year":"2017","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ymthe.2024.03.032_bib23","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.032_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.032_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.03.032_bib26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.03.032_bib27","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.03.032_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/bbmt.2003.50024","article-title":"Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy","volume":"9","author":"Krance","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2024.03.032_bib29","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.032_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2024.03.032_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2019.05.015","article-title":"Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application","volume":"14","author":"Schott","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2026.04.029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000}},{"DOI":"10.1016\/j.ymthe.2026.04.029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:19Z","timestamp":1776802999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1525001624002107"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.032","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}